Gregory D. Perry - 25 Feb 2022 Form 4 Insider Report for Finch Therapeutics Group, Inc. (FNCH)

Reporting relationship: Chief Financial Officer
Issuer ticker: FNCH
Reported as of: 25 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Feb 2022, 17:50:33 UTC
Prior SEC filing: 21 Jun 2021
Next SEC filing: 02 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Trey Reilly, Attorney-in-Fact

Key filing fact

Gregory D. Perry filed Form 4 for Finch Therapeutics Group, Inc. (FNCH) on 28 Feb 2022.

Key facts

This page summarizes Gregory D. Perry's Form 4 filing for Finch Therapeutics Group, Inc. (FNCH).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Feb 2022, 17:50.

Change

Previous filing in this sequence was filed on 21 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FNCH transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +80,000
Change %
Price: $0.000000
Shares after: 80,000
Date: 25 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,000
Exercise price: $8.61
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option vests in equal monthly installments over a four-year period commencing on February 1, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.